Ironwood Pharmaceuticals (IRWD): Today's Weak On High Volume Stock

Trade-Ideas LLC identified Ironwood Pharmaceuticals ( IRWD) as a weak on high relative volume candidate. In addition to specific proprietary factors, Trade-Ideas identified Ironwood Pharmaceuticals as such a stock due to the following factors:

  • IRWD has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $17.1 million.
  • IRWD has traded 143,370 shares today.
  • IRWD is trading at 4.34 times the normal volume for the stock at this time of day.
  • IRWD is trading at a new low 3.04% below yesterday's close.

'Weak on High Relative Volume' stocks are worth watching because major volume moves tend to indicate underlying activity such as material stock news, analyst downgrades, insider selling, selling from 'superinvestors,' or that hedge funds and traders are piling out of a stock ahead of a catalyst. Regardless of the impetus behind the price and volume action, when a stock moves with strength and volume it can indicate the start of a new trend on which early investors can capitalize (or avoid losses by trimming weak positions). In the event of a well-timed trading opportunity, combining technical indicators with fundamental trends and a disciplined trading methodology should help you take the first steps towards investment success.

EXCLUSIVE OFFER: Get the inside scoop on opportunities in IRWD with the Ticky from Trade-Ideas. See the FREE profile for IRWD NOW at Trade-Ideas

More details on IRWD:

Ironwood Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, and commercialization of human therapeutic products. Currently there are 4 analysts that rate Ironwood Pharmaceuticals a buy, no analysts rate it a sell, and 4 rate it a hold.

If you liked this article you might like

Ironwood Shares Jump on FDA Approval for Hyperuricemia Drug - Biotech Movers

5 Ways Allergan Can Keep Up Momentum

Premarket Biotech Movers: Ironwood Pharmaceuticals, Rigel Pharmaceuticals, FibroGen

Synergy Pharmaceuticals Secures Approval for Linzess Competitor